Holen Sie sich die Stockscreener-App
3.33
2.78%
0.09
Vorhandelsmarkt:
3.39
0.06
+1.80%
Schlusskurs vom Vortag:
$3.24
Offen:
$3.39
24-Stunden-Volumen:
109.02K
Relative Volume:
0.16
Marktkapitalisierung:
$7.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.71M
KGV:
-0.2844
EPS:
-11.71
Netto-Cashflow:
$-18.24M
1W Leistung:
+17.67%
1M Leistung:
-16.75%
6M Leistung:
-79.15%
1J Leistung:
-93.53%
1-Tages-Spanne:
$3.24
$3.39
1-Wochen-Bereich:
$3.0835
$3.68
52-Wochen-Spanne:
$2.61
$63.00
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Vergleichen Sie GNPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
3.33 | 7.36M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
MSN Money - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - Setenews
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) - Aktiellt
Can Genprex Inc. stock beat market expectations this quarterMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
Taking the lead: Genprex Inc (GNPX) - Setenews
How Genprex Inc. (2DE0) stock reacts to new regulations2025 Market Trends & Daily Volume Surge Signals - BỘ NỘI VỤ
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Australia
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex keeps Nasdaq listing with bid-price fix, equity waiver granted - Stock Titan
Genprex reports phase 1 data for lung cancer gene therapy By Investing.com - Investing.com Nigeria
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Tria - GuruFocus
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Can - GuruFocus
Genprex reports phase 1 data for lung cancer gene therapy - Investing.com
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PR Newswire
Genprex files prospectus supplement for up to $75 million at-the-market offering By Investing.com - Investing.com Australia
Genprex files prospectus supplement for up to $75 million at-the-market offering - Investing.com Australia
Genprex Inc. (GNPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Genprex Announces $75 Million Stock Offering - MSN
[S-1] Genprex, Inc. Files IPO Registration Statement | GNPX SEC FilingForm S-1 - Stock Titan
Genprex, Inc. Announces $75 Million Stock Offering - TradingView
[8-K] Genprex, Inc. Reports Material Event | GNPX SEC FilingForm 8-K - Stock Titan
Can Genprex Inc. (2DE0) stock sustain revenue momentumWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
How Genprex Inc. stock benefits from tech adoption2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Is Genprex Inc. stock attractive for retirement portfoliosJuly 2025 Breakouts & High Conviction Trade Alerts - newser.com
Why Genprex Inc. (2DE0) stock attracts wealthy investorsPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Is Genprex Inc. (2DE0) stock at risk of policy regulationWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Will Genprex Inc. (2DE0) stock outperform global peersJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Published on: 2025-11-19 22:26:30 - newser.com
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):